As expected, in vivo BLI signals were stronger in LOXL4-knockdown tumor sites (6.13×107 p/s/cm2/sr) than in control tumor sites (468.54×107 p/s/cm2/sr) (Figure 3B–3C, P = 0.035). This evidence concerns the gene LOXL4 and neoplasm.